Press Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 11, 2012
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) determined that Eisai has met the FDA's Written Request requirements...
-
Dec 7, 2012
Results from the first large, global Phase III study of Halaven(®) (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer...
-
Nov 30, 2012
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA)...
-
Nov 28, 2012
Eisai Inc. announced today that six abstracts highlighting new study results will be presented during the 2012 CTRC-AACR San Antonio Breast...
-
Nov 26, 2012
Following a productive first year of headcount growth and scientific advancement, H3 Biomedicine Inc. (H3), a biopharmaceutical company specializing...